Andrew Dudum

Last updated
Andrew Dudum
Alma materUniversity of Pennsylvania (Wharton School)
OccupationEntrepreneur
Years active2010–present
Known forFounder and CEO of Hims & Hers Health
TitleCEO, Hims & Hers Health

Andrew Dudum is a Palestinian-American entrepreneur who is the founder and CEO of telehealth startup Hims & Hers Health, Inc.

Contents

Early life and education

Dudum was born and raised in San Francisco, California. He is an American of Palestinian heritage. He trained as a classical cellist and performed live across the United States and Europe, at hundreds of concerts and weddings, including at Carnegie Hall. [1] He attended the Wharton School of the University of Pennsylvania, where he studied Management and Economics. Dudum did not finish his degree and is therefore a college dropout. [2]

Career

While in college, Dudum co-founded LendforPeace, a nonprofit microlending site for Middle Eastern entrepreneurs. He later worked at TokBox, a video-chat startup that was eventually acquired. [1] The acquisition of TokBox freed Dudum up to pursue his goal to build a startup. In 2013, Dudum co-founded Atomic Labs, a San Francisco-based startup studio backed by investors such as Peter Thiel and Marc Andreessen. Atomic launched companies including Bungalow, Homebound, TalkIQ, and Terminal. [2] [3] In 2016, Dudum founded Hims, a direct-to-consumer telehealth startup, still as part of Atomic. He has served as CEO since its inception. [2] The company expanded into women's health under the brand Hims & Hers, offering online consultations, prescriptions, and over-the-counter products. [4] [ circular reference ] Hims raised over US$100 million in funding and became a “unicorn” in 2019. In 2020, Hims went public via a SPAC at a $1.6 billion valuation, debuting on the New York Stock Exchange in January 2021 under the ticker NYSE :  HIMS. [5] In 2024, Hims & Hers expanded into GLP-1 weight loss medicine and generated annual revenues of $1.48 billion. [6] [7] [8] Andrew Dudum has a net worth of approximately $1 billion. [9] [10]

Controversies

In 2024, Dudum drew both praise and some criticism for a social media post in which he encouraged companies to hire student protesters involved in anti-Israel demonstrations. He later clarified his statement as support for peaceful protest and free speech. [1] [11]

In 2025, his San Francisco donut shop, George's Donuts & Merriment, drew local backlash after a $1 million Hims & Hers donation to President Donald Trump's inaugural committee became public. [12]

See also

References

  1. 1 2 3 "Andrew Dudum: Founder and CEO of Hims & Hers". Quartr. 4 December 2024. Retrieved 2 September 2025.
  2. 1 2 3 "Andrew Dudum – Board of Directors". Hims & Hers Investor Relations. Retrieved 2 September 2025.
  3. "Andrew Dudum - HIMS | Hims & Hers Health Inc. - Wall Street Journal". www.wsj.com. Retrieved 2025-09-01.
  4. "Hims & Hers Health". Wikipedia. Retrieved 2 September 2025.
  5. "Telehealth company Hims to go public via SPAC". Reuters. 1 October 2020. Retrieved 2 September 2025.
  6. "How Novo Nordisk Rival Hims Became King of Knockoff Weight-Loss Drugs". Bloomberg.com. Archived from the original on 2025-08-25. Retrieved 2025-09-01.
  7. "Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results" (PDF). Hims & Hers Health, Inc. February 24, 2025. Retrieved 2 September 2025.
  8. Niasse, Amina (2025-06-10). "Hims & Hers says its weight-loss business can grow as US market changes". Reuters. Retrieved 2025-09-01.
  9. McEvoy, Jemima. "Cofounder Of Hims, Seller Of Hair Loss And Erectile Dysfunction Pills, Is A Billionaire After Weight Loss Drug Deal". Forbes. Retrieved 2025-09-01.
  10. "Hims CEO Rides Weight-Loss Drug Boom to $1.1 Billion Fortune". Bloomberg.com. Archived from the original on 2025-08-25. Retrieved 2025-09-01.
  11. Revell, Eric (2024-05-02). "Hims founder offers jobs to anti-Israel protesters, hails their 'moral courage'". FOXBusiness. Retrieved 2025-09-01.
  12. "San Francisco donut shop tied to Hims CEO faces backlash over Trump donation". San Francisco Chronicle. 28 August 2025. Retrieved 2 September 2025.